Search

Your search keyword '"Corbu I"' showing total 9 results
Start Over Author "Corbu I"
9 results on '"Corbu I"'

3. Up to date concepts about Von Willebrand disease and the diagnose of this hemostatic disorder.

Author

Buga-Corbu, I. and Arion, C.

Subjects
*VON Willebrand disease, *HEMORRHAGE, *VON Willebrand factor, *FIBRINOGEN, *ENZYME-linked immunosorbent assay
Abstract

The authors review the current data in literature regarding the recent knowledge about hemostase, coagulation and clinical and laboratory diagnostic algorithms of hemostatic disorders. They also present the pathological classification of bleeding disorders - the basis to clinical approach of these diseases. [ABSTRACT FROM AUTHOR]

Published
2014

4. Current therapy in children and adolescents with von Willebrand disease.

Author

Buga-Corbu, I. and Arion, C.

Subjects
*VON Willebrand disease, *BLOOD coagulation disorders, *GENETIC disorders, *HEMORRHAGIC diseases, *HEMORRHAGE, *JUVENILE diseases
Abstract

The article represents a review of recent data about the therapy of von Willebrand disease In children and adolescents (hereditary as well as acquired forms of the disease). The treatment of bleeding events In these patients, the Indications In different subtypes, and the future lines of research are mentioned. [ABSTRACT FROM AUTHOR]

Published
2014

5. SEAWATER ELECTROLYSIS FOR HYDROGEN PRODUCTION.

Author

Badea, G. E., Corbu, I., Caraban, A., and Cret, P.

Subjects
WATER electrolysis, SEAWATER, HYDROGEN production, STEADY-state flow, IMPEDANCE spectroscopy, NICKEL, WAVE energy, CHEMICAL kinetics
Abstract

A perspective procedure for an environmentally-clean commercial production of hydrogen by seawater as an „in situ" utilisation of marine wave generated power is the seawater electrolysis. In this paper original studies in seawater, using the methods of steady-state polarisation curves and the impedance spectroscopy were made on Ni. [ABSTRACT FROM AUTHOR]

Published
2011

6. Current therapy in children and adolescents with von Willebrand disease

Author

Buga-Corbu, I. and constantin virgiliu arion

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, Factor VIII, Adolescent, Von Willebrand disease, prophylaxis and treatment, Blood Loss, Surgical, Hemorrhage, Prognosis, Case Presentation, von Willebrand Diseases, Platelet Adhesiveness, children and adolescents, hemic and lymphatic diseases, von Willebrand Factor, Disease Progression, Humans, Deamino Arginine Vasopressin, Child, Immunosuppressive Agents, circulatory and respiratory physiology
Abstract

The article represents a review of recent data about the therapy of von Willebrand disease in children and adolescents (hereditary as well as acquired forms of the disease). The treatment of bleeding events in these patients, the indications in different subtypes, and the future lines of research are mentioned. Abbreviations: Ag VWF = von Willebrand antigen, VWD = von Willebrand disease, DDAVP = arginine-vasopressin, EACA = epsilon aminocaproic acid, VWF = von Willebrand factor, VIIc F = the VIIth factor of coagulation, VIIIc F = the VIIIth factor of coagulation, IgG = immunoglobulin G, T/2 = half-time, WVF – Rco = the ristocetin cofactor.

9. Study of specific immune response to unadsorbed concentrated tetanus vaccine administered by intradermal route to non-immunized persons in the last ten years.

Author

Dimache G, Stoean C, Durbacă S, Croitoru M, Ionescu M, Nedelcu IN, and Corbu I

Subjects
Adsorption, Adult, Aged, Antibodies, Bacterial blood, Clostridium tetani immunology, Dose-Response Relationship, Immunologic, Female, Humans, Immunization, Injections, Intradermal, Injections, Intramuscular, Male, Middle Aged, Tetanus Toxoid administration & dosage, Tetanus Toxoid adverse effects, Time Factors, Antibody Specificity immunology, Tetanus Toxoid immunology
Abstract

Investigations of anti-tetanus response, in 404 subjects, most of them aged 60, being non-immunized for at least 10 years, stressed out the fact that 28.7% were not protected and 6.18% presented a protecting titer of 0.01 IU/ml, evaluated by "in vivo" protection test in mice. Some subjects were immunized with unadsorbed Tetanus vaccine (10 Lf/0.1 ml/dose) by i.d. route, using Jet-injector, and the others with adsorbed Tetanus vaccine (0.5 ml/dose), by i.m. route, using the needle and syringe. The vaccines were well tolerated and adverse reactions were not recorded. After 30 days, a single vaccine dose produced a protecting effect in 97.45% of non-protected subjects, belonging to i.d. immunized group, and also in 93.33% belonging to i.m. immunized group. 30 days after the administration of a second dose, protection set up in all subjects, no matter of vaccine type and administration route used. For a continuous reduction of tetanus morbidity, the authors suggest a specific periodical immunization of non-protected persons, selected by serological screening, using unadsorbed Tetanus vaccine, administered by i.d. route by means of the Jet-injector.

Published
1990

Catalog

Books, media, physical & digital resources
See catalog results